APOTEX CORP. for APOTEX CORP.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
S. 2296, the National Defense Authorization Act for 2026, Section 878, Country-of-Origin Disclosure Requirements for Generic Drugs Purchased by the Department of Defense, provisions relating to prohibiting the Department of Defense from procuring for resale any generic drug unless the seller of such generic drug discloses the country the drug was manufactured in and the country of origin of all active pharmaceutical ingredients and key starting materials; Federal policy relating to providing incentives and federal funding to strengthen capabilities for domestic manufacturing of generic drugs; and Federal policy relating to inspection of foreign generic drug manufacturing facilities.
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Health Issues HCR
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; and HR 1483/S. 1302, The Increasing Transparency in Generic Drug Applications Act, provisions relating to the Food and Drug Administrations authority to share information about ingredients and deviations in inactive ingredient concentration with generic pharmaceutical product applicants.
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Tariff (miscellaneous tariff bills) TAR
Executive Order 14231 and 14325, Amendment to Duties To Address the Flow of Illicit Drugs Across our Northern Border, provisions relating to the imposition of tariffs on products from Canada and the exemption of pharmaceuticals compliant with the United States-Mexico-Canada trade agreements from such tariffs; Executive Order 14257, Regulating Imports With A Reciprocal Tariff To Rectify Practices That Contribute To Large And Persistent Annual United States Goods Trade Deficits, provisions relating to the exemption of pharmaceuticals from reciprocal tariffs; Executive Order 14326, Further Modifying the Reciprocal Tarriff Rate, provisions relating to a zero percent tariff rate for non-patented articles for use in pharmaceutical applications; Federal policy relating to the United States-European Union Framework on an Agreement on Reciprocal, Fair, and Balanced Trade and the exemption of generic pharmaceuticals and their ingredients and precursor materials from tariffs; and Federal policy relating to the Department of Commerce's Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients [Docket No. 250414-006] and the exemption of pharmaceuticals compliant with the United States-Mexico-Canada trade agreement from any tariffs implemented following the completion of the Section 232 investigation.
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.